SCHEMBL1322979

SCHEMBL1322979

CCOC(=O)C1CC(=O)NC1=O

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.49
MAPT P10636 3/20 0.49
KDM4E B2RXH2 3/20 0.49
ALDH1A1 P00352 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
GAA P10253 2/20 0.49
HPGD P15428 1/20 0.49
HSD17B10 Q99714 1/20 0.49
LMNA P02545 2/20 0.47
ADORA2B P29275 1/20 0.41
HTT P42858 2/20 0.41
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
POLB P06746 1/20 0.39
TLR4 O00206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10603303 0.83 NPC1 (0.48) KDM4EALDH1A1KMT2AHPGDLMNA
SCHEMBL10832062 0.83 CRBN (0.43) RAB9AMAPTKDM4EALDH1A1MEN1
SCHEMBL9546789 0.80 GAA (0.38) RAB9AMAPTKDM4EALDH1A1MEN1
SCHEMBL6619679 0.80 RAB9A (0.37) RAB9AMAPTKDM4EALDH1A1MEN1
SCHEMBL11022447 0.79 TSHR (0.39) KDM4EALDH1A1KMT2AGAAHTT
SCHEMBL27296485 0.79 MAP3K14 (0.33) RAB9AMAPTKDM4EALDH1A1MEN1
SCHEMBL6328278 0.78 ALDH1A1 (0.36) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL29967266 0.76 MAPK1 (0.42) ALDH1A1MEN1KMT2AGAAADORA2B
SCHEMBL14809551 0.76 MAPT (0.43) RAB9AMAPTKDM4EALDH1A1MEN1
SCHEMBL10361090 0.76 KDM4E (0.53) RAB9AMAPTKDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415487-B2 Process for preparing (3R)-2′-(4-bromo-2-fluorobenzyl)spiro-[pyrrolidine-3,4′(1′H)-pyrrolo[1,2-A]pyrazine]-1′,2,3′,5(2H′)-tetraone DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-04-09 US disclosed
US-8389742-B2 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the same, and use of the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-03-05 US disclosed
US-8389742-B2 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the same, and use of the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-03-05 US disclosed
US-8389742-B2 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the same, and use of the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-03-05 US disclosed
US-20120010405-A1 OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND TANAKA DAISUKE (JP) 2012-01-12 US disclosed
US-8058456-B2 Optically active 3-amino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the compound, and use of the compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-11-15 US disclosed
US-8003808-B2 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylates, process for production of the same, and use of the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-08-23 US disclosed
US-8003808-B2 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylates, process for production of the same, and use of the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-08-23 US disclosed
US-20110201807-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME TANAKA DAISUKE 2011-08-18 US disclosed
US-20110201807-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME TANAKA DAISUKE 2011-08-18 US disclosed
US-20090286980-A1 OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-11-19 US disclosed
US-20090253917-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATES, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-10-08 US disclosed
US-20090253917-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATES, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-10-08 US disclosed
EP-0148777-B1 PHOSPHOLIPIDS, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1988-07-27 EP disclosed
US-4650791-A ASTHMA Takedo Chemical Industries, Ltd. (JP) 1987-03-17 US disclosed
US-4578378-A (Oxoheterocyclic carbonamido)cephem carboxylic acid derivatives SHIONOGI & CO., LTD. (JP) 1986-03-25 US disclosed
EP-0148777-A2 Phospholipids, their production and use Takeda Chemical Industries, Ltd. (JP) 1985-07-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253917-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATES, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME SLC5A1, TERT, CBR3 RAB9A 1161/4885MAPT 494/4885KDM4E 1902/4885
US-20090286980-A1 OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND REN, GPR119, RANBP1 RAB9A 266/4885MAPT 251/4885KDM4E 2004/4885
US-20120010405-A1 OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND REN, GPR119, RANBP1 RAB9A 266/4885MAPT 251/4885KDM4E 2004/4885
US-20110201807-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME CBR3, TERT, NOX4 RAB9A 866/4885MAPT 429/4885KDM4E 1858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.